Dr. Neal Gaither

System Associate Director for Interventional Cardiology Executive Director of the Cardiac Catheterization Laboratories for Inova Co-Director of Complex Coronary Therapeutic Program Dr. Behnam N. Tehrani also serves as an assistant clinical professor of medicine at both George Washington University and the University of Virginia. He is involved in clinical trials and registries pertaining to complex coronary interventions, renal denervation, cardiogenic shock and pulmonary embolism. In line with Inova’s mission and values, Dr. Tehrani has dedicated his career to the development of team-based systems of care – bringing together specialists to collaborate on patient care, using innovative technologies coupled with research and a lifelong commitment to education and learning. He played a key role in creating Inova’s cardiogenic shock team, which has become a national leader in improving survival rates for this life-threatening condition. He also co-leads the team that performs advanced, technically complex catheter-based procedures for patients with severe coronary artery disease who are at elevated risk and often have limited treatment options. This includes procedures for chronic total occlusion, a complete blockage in the coronary arteries. Dr. Tehrani is also part of the team that introduced renal denervation services for treating resistant hypertension, as well as the rapid-response team for diagnosing and treating pulmonary embolism and the team that treats chronic thromboembolic pulmonary hypertension. Recognized nationally for his leadership, Dr. Tehrani serves on committees for both the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. He has co-authored more than 100 peer-reviewed publications, abstracts and book chapters, with his work published in top medical journals including Journal of the American College of Cardiology (JACC), JACC: Heart Failure, JACC: Cardiovascular Interventions, JAMA Cardiology, Circulation: Heart Failure, and Journal of the Society for Cardiovascular Angiography and Interventions. He also contributes as a peer reviewer for Journal of the American College of Cardiology, Circulation, European Heart Journal, American Heart Journal, and Catheterization and Cardiovascular Interventions. Dr. Tehrani is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Cardiogenic Shock, Heart Attack, Pulmonary Hypertension, Percutaneous Coronary Intervention (PCI), and Lithotripsy.

Alexander Truesdell is an Interventional Cardiologist practicing medicine in Falls Church, Virginia. Dr. Truesdell is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Cardiogenic Shock, Heart Attack, Carotid Artery Disease, Percutaneous Coronary Intervention (PCI), and Angioplasty.

President, Inova Medicine Service Line Schar Chair, Inova Schar Heart and Vascular Director Emeritus, Interventional Cardiology, Inova Professor of Medicine, Duke University School of Medicine Wayne Batchelor, MD, MHS, MBA, is President of the Medicine Service Line. He joined Inova in 2019 with more than two decades of executive leadership in academic medicine, private practice, clinical research, and education. He is Professor of Medicine (adj.), Duke University, Chair of the American College of Cardiology (ACC) Interventional Sectional Leadership Council, and Vice-Chair of the STS/ACC Transcatheter Valve Therapy (TVT) Registry. He has previously served as an academic cardiologist at the University of Toronto, President of Southern Medical Group, PA in Tallahassee, Florida, Board Member of Tallahassee Memorial Healthcare, and Co-Founder/President of the Tallahassee Research Institute (TRI). He is internationally recognized for his clinical and research expertise in interventional cardiology, clinical trials, outcomes research, regulatory science, and healthcare disparities in medicine. Fostering multidisciplinary collaborations within and between service lines, Dr. Batchelor has successfully built innovative clinical programs and improved patient outcomes within both private practice and academic medical settings. He has published more than 200 peer-reviewed abstracts and manuscripts, multiple book chapters, served on numerous clinical trial steering committees and as National Principal Investigator (PI) on landmark clinical trials in cardiovascular medicine. He is a special consultant to the U.S. Food and Drug Administration (FDA) within the Cardiovascular Devices Branch, has served on the editorial boards for Circulation, the Journal of the Society of Cardiovascular Angiography and Interventions, and Cardiovascular Revascularization Medicine and is a Senior Advisor and frequent Guest Editor for the Journal of the American College of Cardiology. Dr. Batchelor earned his bachelor of science and medical degree from Queens University in Kingston, Ontario, Canada, a master's degree in clinical research from Duke University, and an Executive MBA from New York University. Dr. Batchelor is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Cardiogenic Shock, Mitral Valve Regurgitation, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR), and Aortic Valve Replacement.